Related Experiment Video
Updated: Aug 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Prezista (darunavir, TMC-114) approved; may be important treatment advance
Abstract:
A major new antiretroviral has been approved, for patients resistant to more than one protease inhibitor. There is no information yet on risk/benefit compared to standard treatments for first-line use. Tibotec, which developed the drug and is now part of Johnson & Johnson, showed price restraint and avoided setting a new record high price, which other companies have done.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Therapeutic Drug Monitoring: Affecting Factors
FDA Approved Drugs: Changes to Approved Drugs
Antiprotozoal Agents
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Therapeutic Drug Monitoring: Overview and Classification
